The implication of the FDA's interpretation of the law, if upheld by the court, would mean that all food, drugs, devices, and biologic or cosmetic products would be subject to FDA jurisdiction. The FDA is expanding its reach even to commerce within the state, which we argue is far beyond its jurisdiction, in order to protect drug company
Glaucoma is the second leading cause of blindness worldwide, but it is surrounded by many mysteries yet to be solved by researchers. Additionally, the general public is not well informed about the risks of glaucoma. “It is estimated that over 2.2 million Americans have glaucoma but only half of those know they have it” (“Glaucoma Facts”, 2013, para. 8). Glaucoma is a disease in which continual pressure to the optic nerve damages it, leading to vision loss (“What is Glaucoma?”, n.d.). Glaucoma is complicated and not very well known. It is important to raise public awareness about this condition so that people with a high risk can have access to testing, glaucoma can be treated properly, and a cure can be found. Therefore, it is essential to know the effects and symptoms, testing methods, potential treatments, genetic causes, and risk groups for glaucoma in order to become more aware for the benefit of individuals with and without glaucoma.
Glaucoma in the United States Over the Last Ten Years This research paper examines glaucoma over the age of 40 in the United States, in the last 10 years. Knowing the fact that glaucoma is the second leading cause of blindness in the United States leads us to choose this subject for research. Glaucoma is a group of eye diseases that gradually steals sight without warning and often without symptoms. Vision loss is caused by damage to the optic nerve. This nerve acts like an electric cable with over a million wires and is responsible for carrying the images we see to the brain.
“Compounding pharmacies in the traditional role make drugs prescribed by doctors for specific patients with needs that can’t be met by commercially available drugs” (DeNoon). “The Food and Drug Administration does not regulate compounding pharmacies. Compounding pharmacies drew national attention in 2012, after a meningitis outbreak killed 64 people and was traced to steroid injections brewed at a compounding pharmacy in Massachusetts” (McClam).
OPHTHALMICS 1. INTRODUCTION Ophthalmics are the sterile liquid, solid or semi- solid preparations may contain one or more pharmaceutical ingredient (s) intended to be administered onto the internal, external surface of the eye or adjacent to the eye. These are essentially free from foreign particles or viable microorganism, suitably compounded and packaged for easy instillation into the eye. The excipients added should not affect the stability of the product and the availability of the active ingredients at the site of action.
The current Food and Drugs Regulations appear quite solid. Definitions are made for a variety of terms such as “daily value”, and rules are made with very specific scopes, breaking down stakeholders (consumers, producers/retailers) into groups so that there is s...
fight against the abuse of drugs and other substances. Even though the federal legislation has an impact on pharmacy, the CSA exerts a more direct impact, as the law requires registration, specific record keeping, and the rules of regarding the dispensing of controlled substances. Penalties for the violation of the CSA are more sever than a violation from the FDC Act. Under the act controlled substances are placed in one of 5 categories. Schedule I drugs can’t be handled by pharmacies. Schedule I drugs have a high potential for abuse and currently have no recognized medical use. Any pharmacy that is found to posses a Schedule I drug is in violation of the CSA, even if the drug was formerly a Schedule II drug. Schedule II drugs have a high potential for abuse, but currently have a medical use. Schedule II drugs have a several specific provisions relevant to pharmacies and pharmacists. One of the essential provisions is the requirement that prescriptions that are to be dispensed for Schedule II medications must be written and then signed by the practitioner. Exceptions to this rule d...
The research article Corticosteroids and Open-Angle Glaucoma in the Elderly was authored by Micheal Marcus, Rogier Müskens, Wishal Ramdas, Rodger Wolfs, Paulus Jong, Johannes Vingerling, Hofman R, Bruno Albert, and Nomdo Jansonius and was published in 2012 in Switzerland. It is the original research article based on the Rotterdam study that examines the link between the use of corticosteroids and open-angle glaucoma (OAG) in the elderly population. This paper will summarize and review the article, discuss the articles accuracy and shortcomings,
Glaucoma is defined as a slow, progressive disease that causes an increase in intraocular pressure against the optic nerve (Potter and Perry, 2015). Glaucoma can also be described as groups of disease that damage the optic nerve in the eye. The optic nerve sends information from the eye to the brain. Most of the time glaucoma is progressive, silent, and can be untreatable if the disease is too far along. Glaucoma causes loss of peripheral vision, central vision and blindness in the later stages (Williams and Hopper, 2015).